Durable Response to Glofitamab in HIV‐Positive Refractory Burkitt Lymphoma: Case Report and Discussion

ABSTRACT Background Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed. Methods We describe a 60‐year‐old HIV‐positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off‐label with glofitamab successfully. Results Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post‐treatment. Conclusion Glofitamab may represent a promising stand‐alone option in relapsed BL, when conventional cytotoxic therapies are exhausted. Clinical Trial Registration : The authors have confirmed that clinical trial registration is not needed for this submission.